|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
Address1 | 6555 State Highway 161 |
Address2 |
|
City | Irving |
State | TX |
Zip Code | 75039 |
Country | USA |
3. Principal place of business (if different than line 2)
City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 24566-12
|
||||||||
|
6. House ID# 313130000
|
TYPE OF REPORT | 8. Year | 2021 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
---|---|---|---|---|---|---|---|---|---|
12. Lobbying | 13. Organizations | ||||||||
INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
Signature | Digitally Signed By: Peter Slone, SVP, Public Affairs |
Date | 1/20/2022 8:50:32 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
The Social Determinants Accelerator Act, S.4264; U.S. MADE Act of 2020, H.R. 6880; MADE in America Act, H.R.3; Oncology Care Model; Radiation Oncology APM; Lower Drug Costs Now Act of 2019, H.R.1845; Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R.748; CARES Act; H.R. 6800 Heroes Act, and COVID-19 vaccine distribution. H.R.2503 - The Social Determinants Accelerator Act of 2021, H.R.3 - Drug pricing and transparency, H.R.3, H.R.19; Budget Reconciliation; International price referencing, H.R.19; Medical Supplies for Pandemics Act of 2021, S.65; Improving Seniors Timely Access to Care Act, H.R. 3173; Safe Step Act, 2163; Buy America and domestic sourcing, strategic national stockpile H.R.3635; S.308; H.R.2780; global operations, trade; Opioids, substance abuse and prescription safety alert systems; Issues remain the same with addition of Build Back Better Act, H.R.5376; Budget reconciliation; Social determinants of health; health disparities in underserved communities; chronic health conditions; Tax policy, LIFO (last in-first out); Drug pricing and transparency; international price referencing H.R. 3 (provisions later included in Build Back Better H.R. 5376); Buy America and domestic sourcing, strategic national stockpile; Covid relief and pandemic response, pandemic preparedness; Supply chain; Pharmacy provider status, retail pharmacy H.R. 2759 (Butterfield); 21st Century CURES 2.0 (H.R. 6000).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Peter |
Slone |
|
|
|
Josh |
Babb |
|
|
|
Damon |
Porter |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Issues related to physician reimbursement for Part B drugs; Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635); Issues as they relate to opioid abuse policy; General Medicare/Medicaid Issues; Issues related to reimbursement for radiation therapy services; 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices; Pandemic and All Hazards Preparedness Act reauthorization; issues related to step therapy policies in Medicare Advantage plans; Medicare physician payment; Issues related to an alternative payment model for radiation oncology services; Issues related to the Center for Medicare and Medicaid Innovation; Issues related to the ANPRM International Pricing Index Model for Medicare Part B Drugs; issues related to the Oncology Care First model, H.R. 4621, the Collecting and Analyzing Resources Integral and Necessary for Guidance (CARING) for Social Determinants Act of 2019, S. 2986/H.R. 4004, the Social Determinants Accelerator Act. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748- CARES Act; H.R. 6800 Heroes Act, and COVID-19 vaccine distribution; H.R. 1868, Sequestration; H.R.2503; Budget reconciliation; Social determinants of health; health disparities in underserved communities; chronic health conditions; Tax policy, LIFO (last in-first out); Drug pricing and transparency; international price referencing H.R. 3 (provisions later included in Build Back Better H.R. 5376); Buy America and domestic sourcing, strategic national stockpile; Covid relief and pandemic response, pandemic preparedness; Supply chain; Pharmacy provider status, retail pharmacy H.R. 2759 (Butterfield); 21st Century CURES 2.0 (H.R. 6000).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, Centers For Medicare and Medicaid Services (CMS)
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ben |
Jones |
|
|
|
Lisa |
Langenderfer |
|
|
|
Tom |
Borck |
|
|
|
Josh |
Babb |
|
|
|
Damon |
Porter |
|
|
|
Peter |
Slone |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Pharmacy issues, prescription drug supply chain issues, drug shortages, prescription drug abuse and diversion; support for legislation to preserve patient access to oral oncolytic dispensed by community-based cancer clinics (H.R. 1316); DIR (H.R. 1038), advocacy related to ending retroactive direct and indirect remuneration fees levied on pharmacists; Provider status (H.R. 592), advocacy related to recognizing and reimbursing pharmacists for providing appropriate medical services; H.R. 6880 - The Buy American Medical Supplies Act, Lower Drug Costs Now Act of 2019. Issues related to Medicare Part D payments; matters related to response to COVID-19 outbreak/H.R. 748 - CARES Act; H.R. 6800, Heroes Act, and COVID-19 vaccine distribution; S.1362; Budget reconciliation; Social determinants of health; health disparities in underserved communities; chronic health conditions; Tax policy, LIFO (last in-first out); Drug pricing and transparency; international price referencing H.R. 3 (provisions later included in Build Back Better H.R. 5376); Buy America and domestic sourcing, strategic national stockpile; Covid relief and pandemic response, pandemic preparedness; Supply chain; Pharmacy provider status, retail pharmacy H.R. 2759 (Butterfield); 21st Century CURES 2.0 (H.R. 6000).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Ben |
Jones |
|
|
|
Lisa |
Langenderfer |
|
|
|
Tom |
Borck |
|
|
|
Josh |
Babb |
|
|
|
Damon |
Porter |
|
|
|
Peter |
Slone |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Tax policy; LIFO-last-in, first-out; foreign earnings, corporate tax rate; Budget reconciliation; Social determinants of health; health disparities in underserved communities; chronic health conditions; Tax policy, LIFO (last in-first out); Drug pricing and transparency; international price referencing H.R. 3 (provisions later included in Build Back Better H.R. 5376); Buy America and domestic sourcing, strategic national stockpile; Covid relief and pandemic response, pandemic preparedness; Supply chain; Pharmacy provider status, retail pharmacy H.R. 2759 (Butterfield); 21st Century CURES 2.0 (H.R. 6000).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Josh |
Babb |
|
|
|
Damon |
Porter |
|
|
|
Peter |
Slone |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAR
16. Specific lobbying issues
Budget reconciliation; Social determinants of health; health disparities in underserved communities; chronic health conditions; Tax policy, LIFO (last in-first out); Drug pricing and transparency; international price referencing H.R. 3 (provisions later included in Build Back Better H.R. 5376); Buy America and domestic sourcing, strategic national stockpile; Covid relief and pandemic response, pandemic preparedness; Supply chain; Pharmacy provider status, retail pharmacy H.R. 2759 (Butterfield); 21st Century CURES 2.0 (H.R. 6000).
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Damon |
Porter |
|
|
|
Josh |
Babb |
|
|
|
Peter |
Slone |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
Address |
|
||||||
City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
1 |
|
3 |
|
||||||
2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% |
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
1 | 3 | 5 |
2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
Lobbyist Name | Description of Offense(s) |